1.	Phase III Randomized Study of Exatecan Mesylate and Gemcitabine Versus Gemcitabine Alone in Patients With Chemotherapy-Naive Locally Advanced or Metastatic Cancer of the Exocrine Pancreas Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: DAIICHI-8951A-PRT031, MSKCC-02011, NCT00023972
2.	Phase II Study of DX-8951f in Patients with Fluorouracil-Resistant Advanced or Metastatic Adenocarinoma of the Colon or Rectum (Summary Last Modified 12/1999) Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: DAIICHI-8951A-PRT007, MSKCC-98103, NCI-G99-1505
3.	Phase II Study of DX-8951f in Patients With Hormone Refractory Prostate Cancer (Summary Last Modified 08/2001) Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: DAIICHI-8951A-PRT012, SACI-IDD-99-03, SLLH-BHS-99-0020, NCT00004045
4.	Phase II Study of DX-8951f in Patients With Metastatic Carcinoma of the Exocrine Pancreas (Summary Last Modified 05/2001) Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: DAIICHI-8951A-PRT009, JHOC-99062405, MSKCC-99014, NCT00003951
5.	Phase II Study of DX-8951f in Women With Metastatic Adenocarcinoma of the Breast Who Have Failed Prior Therapy (Summary Last Modified 04/2002) Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: DAIICHI-8951A-PRT011, MDA-ID-98308, NCT00004046
6.	Phase II Study of DX-8951f in Patients with Recurrent, Metastatic, or Unresectable Ovarian, Tubal, or Peritoneal Carcinoma (Summary Last Modified 09/2000) Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: DAIICHI-8951A-PRT008, MDA-DM-98265, NCT00004060
7.	Phase II Study of DX-8951f in Patients With Hepatocellular Carcinoma (Summary Last Modified 08/2001) Phase: Phase II Type: Treatment Status: Closed Age: 16 and over Sponsor: Pharmaceutical / Industry Protocol IDs: DAIICHI-8951A-PRT016, MDA-ID-99145, MSKCC-99058, UCHSC-00891, NCT00004108
8.	Phase II Study of DX-8951f in Women With Advanced or Recurrent Squamous Cell Carcinoma of the Cervix Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: DAIICHI-8951A-PRT015, MDA-DM-99247, NCT00004866
9.	Phase II Study of DX-8951f in Previously Untreated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: DAIICHI-8951E-PRT017, EU-99044, NCT00005091
10.	Phase II Study of DX-8951f in Patients With Biliary Tree Cancer (Summary Last Modified 08/2001) Phase: Phase II Type: Treatment Status: Closed Age: 16 and over Sponsor: Pharmaceutical / Industry Protocol IDs: DAIICHI-8951A-PRT020, MDA-ID-99379, MSKCC-99110, SACI-IDD-99-31, UCHSC-00892, UTHSC-9905011256, NCT00005938
11.	Phase II Study of Exatecan Mesylate (DX-8951f) in Patients With Previously Untreated Metastatic Gastric Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: DAIICHI-8951A-PRT028, SACI-IDD-00-27, UTHSC-0015011134, NCT00017212
12.	Phase II Study of Exatecan Mesylate in Patients With Advanced Soft Tissue Sarcoma Phase: Phase II Type: Treatment Status: Closed Age: 15 to 75 Sponsor: Other Protocol IDs: EORTC-62006, NCT00041236
13.	Phase II Study of Exatecan Mesylate in Pediatric Patients With Relapsed or Refractory Rhabdomyosarcoma Phase: Phase II Type: Treatment Status: Closed Age: Any age Sponsor: Pharmaceutical / Industry Protocol IDs: DAIICHI-8951A-PRT033, SJCRH-DXRMS, NCT00055939
14.	Phase II Study of Exatecan Mesylate in Patients With Ewing's Sarcoma, Primitive Neuroectodermal Tumor, or Desmoplastic Small Round Cell Tumor Phase: Phase II Type: Treatment Status: Closed Age: Any age Sponsor: Pharmaceutical / Industry Protocol IDs: DAIICHI-8951A-PRT034, SJCRH-DXEWS, NCT00055952
15.	Phase I Study of DX-8951f in Patients with Advanced Myelodysplastic Syndromes, Refractory Acute Myeloid or Lymphocytic Leukemia, Refractory or Transformed Chronic Lymphocytic Leukemia, or Chronic Myelogenous Leukemia in Blastic Phase (Summary Last Modified 09/2000) Phase: Phase I Type: Treatment Status: Completed Age: Not specified Sponsor: Pharmaceutical / Industry Protocol IDs: DAIICHI-8951A-PRT014, MDA-ID-99013, NCI-V99-1556, NCT00004047
16.	Phase I Study of Exatecan Mesylate (DX-8951f) With and Without Filgrastim (G-CSF) in Pediatric Patients With Advanced Solid Tumors or Lymphomas Phase: Phase I Type: Treatment Status: Completed Age: 21 and under at diagnosis Sponsor: Pharmaceutical / Industry Protocol IDs: DAIICHI-8951A-PRT013, MSKCC-99071, UTHSC-9895011445, NCI-V99-1573, NCT00004212
17.	Phase I Study of Exatecan Mesylate in Patients With Advanced Solid Tumors and Varying Degrees of Renal Dysfunction Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-0201008, DAIICHI-8951A-PRT026, NCI-G02-2103, NCT00045318